IMPACT: a UK clinical trials programme for hemonc patients post-transplant
Cellular therapies in lymphoma
Small molecule-chemotherapy combinations: ibrutinib plus rituximab for CLL
An overview of the lymphoma landscape from BSH 2017
The rise of MRD in multiple myeloma: could this be an answer to a cure?